July 2026
M	T	W	T	F	S	S
	1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

Aurelio Maggio: Is It Time to Align Thalassemia Biology with Regulatory Science?

Aurelio Maggio/LinkedIn

Feb 22, 2026, 06:43

Aurelio Maggio: Is It Time to Align Thalassemia Biology with Regulatory Science?

Aurelio Maggio, President of Foundation Franco and Piera Cutino, shared on LinkedIn:

”A Century After Cooley: Is It Time to Align Thalassemia Biology with Regulatory Science?

March 18–21, 2027 | Palermo, Italy
International GRADE-Based Consensus Conference

GARDEN Network – Global Hematological Rare Diseases Alliance

In 1925, Thomas Benton Cooley described what he called ‘Erythroblastic Anemia’, recognizing a profound disturbance in erythroid development.

More than a century later, thalassemia remains primarily classified as a globin gene disorder.

That molecular basis remains central.

However, translational evidence is expanding the framework.

Dysregulated hematopoietic stem cell (HSC) biology.

Persistent stress erythropoiesis. Metabolic hyperactivation. Epigenetic modulation.

These mechanisms appear to influence phenotypic heterogeneity, treatment responsiveness, disease-modifying potential, and long-term organ outcomes.

This is not a semantic issue. It is a regulatory one.

A stem cell–centered model could impact:

Mechanism-based endpoint selection
Biomarker qualification strategies
Trial population stratification
Surrogate endpoint validation
Long-term follow-up architecture

In March 2027, we will convene the first international GRADE-based structured consensus to systematically assess this framework.

The goal is alignment — between biology, therapeutic innovation, and regulatory evaluation.

We welcome dialogue with regulatory authorities, HTA bodies, and industry partners interested in biologically coherent development strategies in rare hematologic diseases.

A century after its original description, reassessment may not be disruptive — it may be necessary.”